Clinical trial NCT04486755: Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
Official title: A Phase I Dose Escalation Study of Hypofractionated Accelerated Pelvic Nodal Radiotherapy Delivered With A Simultaneously Integrated Prostate Boost For Patients With Localized, Intermediate- And High-Risk Prostate Cancer (GCC 2048)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Prostate Cancer
Prostate Adenocarcinoma
Keywords: Prostate
Hypofractionated Radiation Therapy
Prostate Cancer
Radiotherapy
Proton Therapy
Lead sponsor: University of Maryland, Baltimore
Sponsor class: OTHER
First posted: 2020-07-27
Enrollment: 18
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: A modified 3+3 study design will be employed to determine the dose-fractionation schedule that results in less than 33% dose limiting toxicity. One de-escalation will be allowed if the initial dose-fractionation schedule results in too high a frequency of dose limiting toxicities. A total of 6 patients will be treated following the dose-fractionation schedule that is recommended for further study.
Primary purpose: TREATMENT

Brief summary: A phase I trial to determine the safety of delivering three sequentially shorter RT schedules (20, 16, and 12 fractions) of HypoFx pelvic nodal RT in combination with a HypoFx, simultaneous integrated boost (SIB) to the prostate that have been designed to incrementally increased the biological equivalent dose (BED) to prostate cancer, while maintaining a constant BED to normal tissue toxicity.

Detailed description: Outcomes for patients with unfavorable intermediate-risk and high-risk prostate cancer (PC) have been historically poor and are now known to require multimodality treatment. A standard non-surgical treatment option for patients with localized, intermediate and high-risk PC is radiation therapy (RT) in combination with short- or long-term androgen deprivation therapy (ADT).

The benefit of pelvic nodal RT in this setting is unclear, previous studies have been equivocal. There is a growing body of evidence to demonstrate that use of hypofractionated (HypoFx) RT may be a safe method for increasing the dose of RT, while also decreasing normal tissue toxicity.

Eligibility criteria: Inclusion Criteria:

1. Patient age is ≥ 18 years
2. Pathologically (histologically or cytologically) proven diagnosis of prostatic adenocarcinoma within 180 days of registration.
3. Patient's with intermediate to high risk prostate cancer and must be recommended to undergo pelvic as well as prostatic irradiation.
4. History/physical examination (to include at a minimum digital rectal examination of the prostate and examination of the skeletal system and abdomen) within 90 days prior to registration.
5. Clinically negative lymph nodes as established by imaging (pelvic ± abdominal CT or MR), (but not by nodal sampling, or dissection) within 120 days prior to registration.

   • Patients with lymph nodes equivocal or questionable by imaging are eligible if the nodes are ≤ 1.5 cm.
6. No evidence of bone metastases (M0) on bone scan within 120 days prior to registration.

   • Equivocal bone scan findings are allowed if plain films (or CT or MRI) are negative for metastasis.
7. Baseline serum PSA value performed within 12 weeks (90 days) prior to registration.
8. ECOG Performance Status 0-1
9. Patient must be able to provide study specific informed consent prior to study entry.

Exclusion Criteria:

1. Evidence of distant metastases
2. Regional lymph node involvement
3. Previous radical surgery (prostatectomy), cryosurgery, or HIFU (High-intensity focused ultrasound) for prostate cancer
4. Previous pelvic irradiation or prostate brachytherapy
5. Planned prostate brachytherapy boost
6. Previous or concurrent cytotoxic chemotherapy for prostate cancer
7. Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study.
8. Patients are excluded if they have a history of autoimmune disease that, in the opinion of the treating physician would be a contraindication to pelvic radiation (e.g., active systemic lupus, progressive scleroderma)
9. Patients receiving full-dose anticoagulation or clopidogrel

   • Patients taking 81 mg Aspirin po daily may are still eligible for the study
10. Patients with a history of prior small bowel ulceration

Primary outcomes:
measure: HypoFx RT schedule that results in <33% acute dose-limiting toxicity with accelerated, HypoFx pelvic nodal RT
timeFrame: Within 90 days of completing RT
Secondary outcomes:
measure: Frequency of acute and late GI, GU, hematologic, and neurologic toxicity for each dose cohort
timeFrame: Acute (within 90 days completing RT), Late (occurring > 90 days from treatment), 3-months, 6 months, 1-year and 2 years
measure: Dose volume histogram (DVH) parameters
timeFrame: Within 90 days of completing RT
measure: Evaluate the duration of biochemical progression-free survival
timeFrame: 2 years after completing RT
measure: Patient Reported Outcomes (PROs) related to urinary and bowel function
timeFrame: 1 month after completion of treatment, every 3 months for year 1, and every 6 months during Year 2
measure: Patient Reported Outcomes (PROs) related to urinary function
timeFrame: 1 month after completion of treatment, every 3 months for year 1, and every 6 months during Year 2
measure: Patient Reported Outcomes (PROs) related to urinary and bowel function
timeFrame: 1 month after completion of treatment, every 3 months for year 1, and every 6 months during Year 2
Other outcomes:
Locations:
city: Baltimore
country: United States
facility: Maryland Proton Treatment Center
state: Maryland
Study officials:
References: